The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
The sales proportion of remodulin in 2018 is about 60%, and the sale proportion of Tyvaso is about 23% in 2018.
Segment by Application
The most proportion of treprostinil drugs is used for hospitals, and the proportion in 2018 is about 52%.
Middle East & Africa